CRNX
Price
$46.80
Change
+$10.91 (+30.40%)
Updated
Sep 26, 04:11 PM (EDT)
Capitalization
3.38B
41 days until earnings call
VRDN
Price
$20.37
Change
+$1.29 (+6.76%)
Updated
Sep 26, 04:14 PM (EDT)
Capitalization
1.56B
53 days until earnings call
Interact to see
Advertisement

CRNX vs VRDN

Header iconCRNX vs VRDN Comparison
Open Charts CRNX vs VRDNBanner chart's image
Crinetics Pharmaceuticals
Price$46.80
Change+$10.91 (+30.40%)
Volume$16.05K
Capitalization3.38B
Viridian Therapeutics
Price$20.37
Change+$1.29 (+6.76%)
Volume$2.11K
Capitalization1.56B
CRNX vs VRDN Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. VRDN commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Buy and VRDN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (CRNX: $35.89 vs. VRDN: $19.08)
Brand notoriety: CRNX and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 152% vs. VRDN: 70%
Market capitalization -- CRNX: $3.38B vs. VRDN: $1.56B
CRNX [@Biotechnology] is valued at $3.38B. VRDN’s [@Biotechnology] market capitalization is $1.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, CRNX is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 5 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • CRNX’s TA Score: 5 bullish, 5 bearish.
  • VRDN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CRNX and VRDN are a good buy in the short-term.

Price Growth

CRNX (@Biotechnology) experienced а +1.16% price change this week, while VRDN (@Biotechnology) price change was -2.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.02%. For the same industry, the average monthly price growth was +9.36%, and the average quarterly price growth was +51.87%.

Reported Earning Dates

CRNX is expected to report earnings on Nov 06, 2025.

VRDN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+4.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($3.38B) has a higher market cap than VRDN($1.56B). VRDN YTD gains are higher at: -0.469 vs. CRNX (-29.806). VRDN has higher annual earnings (EBITDA): -340.62M vs. CRNX (-419.62M). CRNX has more cash in the bank: 1.2B vs. VRDN (563M). VRDN has less debt than CRNX: VRDN (21.3M) vs CRNX (49.9M). CRNX has higher revenues than VRDN: CRNX (1.39M) vs VRDN (305K).
CRNXVRDNCRNX / VRDN
Capitalization3.38B1.56B217%
EBITDA-419.62M-340.62M123%
Gain YTD-29.806-0.4696,349%
P/E RatioN/AN/A-
Revenue1.39M305K456%
Total Cash1.2B563M212%
Total Debt49.9M21.3M234%
FUNDAMENTALS RATINGS
CRNX vs VRDN: Fundamental Ratings
CRNX
VRDN
OUTLOOK RATING
1..100
1072
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
6283
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
5044
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (89) in the Pharmaceuticals Major industry is in the same range as VRDN (94) in the Biotechnology industry. This means that CRNX’s stock grew similarly to VRDN’s over the last 12 months.

CRNX's Profit vs Risk Rating (62) in the Pharmaceuticals Major industry is in the same range as VRDN (83) in the Biotechnology industry. This means that CRNX’s stock grew similarly to VRDN’s over the last 12 months.

CRNX's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as VRDN (99) in the Biotechnology industry. This means that CRNX’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Price Growth Rating (44) in the Biotechnology industry is in the same range as CRNX (50) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to CRNX’s over the last 12 months.

VRDN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXVRDN
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
75%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
77%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UBVLX86.11N/A
N/A
Undiscovered Managers Behavioral Val L
DQEIX13.36N/A
N/A
BNY Mellon Global Equity Income - I
TRXCX12.21N/A
N/A
Catalyst/MAP Global Balanced C
HFEIX58.09N/A
N/A
Janus Henderson European Focus I
TEGCX16.30N/A
N/A
Touchstone Sands Cptl Emerg Mkts Gr C